Filing Flows › Comparisons › RNAC vs INO
Cartesian Therapeutics vs Inovio Pharmaceuticals: RNAC and INO compared
Cartesian Therapeutics is the larger company: $78K of revenue in its latest quarter (Q1 2026) against $65K for Inovio Pharmaceuticals (Q1 2025).
Where the money goes: RNAC and INO
Cartesian Therapeutics (RNAC) · Q1 2026
Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
Inovio Pharmaceuticals (INO) · Q1 2025
Inovio Pharmaceuticals, Q1 2025: revenue $65K, net loss $19.7M, operating cash flow −$26.9M. The chart follows the revenue to costs, profit and cash.
| Cartesian Therapeutics (RNAC) | Inovio Pharmaceuticals (INO) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q1 2025 |
| Revenue | $78K | $65K |
| Revenue growth, Y/Y | -93% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$39.2M | −$19.7M |
| Operating cash flow | −$22.1M | −$26.9M |
Questions
Which is bigger, Cartesian Therapeutics or Inovio Pharmaceuticals?
Cartesian Therapeutics is the larger company: $78K of revenue in its latest quarter (Q1 2026) against $65K for Inovio Pharmaceuticals (Q1 2025).
More: Cartesian Therapeutics earnings · how Cartesian Therapeutics makes money · Inovio Pharmaceuticals earnings · how Inovio Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Apr 30, 2026; 10-Q filed May 13, 2025). Fiscal quarters can end on different dates. Not investment advice.